The KFF Health Tracking Poll surveyed 1,479 adults online and by telephone between April 23 and May 1.
It found GLP-1 use, including Ozempic, Wegovy and Mounjaro, was most common for people with diabetes (43%), heart disease (26%) and obesity or overweight (22%).
Here are four other findings:
- Of those who reported ever taking the drugs, 61% said they took it for a chronic condition — either alone (39%) or to also lose weight (23%) — and 38% said they took the drugs solely to lose weight.
- Most adults said they are prescribed these drugs from a primary care physician or specialist (79%), while some report getting drugs from online providers or websites (11%), medical spa or aesthetic medical centers (10%) or elsewhere (2%).
- GLP-1 drugs can top $1,000 for a month’s supply, and 54% of users said it was difficult to afford, including 22% who said it was “very difficult.”
- Awareness of the drug is up since July 2023, with 82% of adults saying they heard at least “a little” about these drugs, compared to 19% in July.